Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
May 27, 2026
-
REGULATORY LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
-
REGULATORY US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
-
COMMENTARY Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
-
BUSINESS Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
-
BUSINESS Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
-
REGULATORY Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
-
ORGANIZATION Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
-
BUSINESS BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
-
BUSINESS Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
-
REGULATORY Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
-
REGULATORY Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
-
REGULATORY Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
-
BUSINESS Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
-
REGULATORY MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
-
REGULATORY Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
-
REGULATORY Mounjaro Hit with 25% Price Cut under Japan’s “SPA-SSS” Re-Pricing
May 14, 2026
-
REGULATORY Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
May 14, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
May 14, 2026
-
REGULATORY Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
May 13, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…